Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis

OBJECTIVE: To summarize the therapeutic effect and safety of bexagliflozin in patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Randomized controlled trials (RCTs) involving patients with T2D receiving bexagliflozin in the intervention arm and either a placebo or any active comparator in t...

Full description

Saved in:

Bibliographic Details
Main Authors:	A.B.M. Kamrul-Hasan, Deep Dutta, Ershad Mondal, Lakshmi Nagendra, Mehedi Hasan, Md. Shahidullah, Kaushik Biswas, Saptarshi Bhattacharya
Format:	Article
Language:	English
Published:	Via Medica 2025-01-01
Series:	Clinical Diabetology
Subjects:	bexagliflozin SGLT2i type 2 diabetes HbA1c hypoglycemia meta-analysis
Online Access:	https://journals.viamedica.pl/clinical_diabetology/article/view/104462
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Heptad green metrics and quality by design tool evaluated chromatography method for content determination of Bexagliflozin in formulation product
by: Satyajit Raj Nethekar, et al.
Published: (2025-06-01)

Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis
by: Zhouhong Zhan, et al.
Published: (2025-07-01)

Analysis of thalassemia genotypes and HbA2 test results in pregnant women in Shenzhen, China
by: Hou Qian, et al.
Published: (2025-03-01)

Modeling recurrent heart failure risk in type 2 diabetes: impact of flexible HbA1c trajectories using nonhomogeneous Poisson processes
by: Di Cui, et al.
Published: (2025-04-01)

Potential Detrimental Interactions Between Metformin and Supplemental Dietary Fiber in Type 2 Diabetes
by: Rosemary M. Hall, et al.
Published: (2025-05-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

A patient choice‐driven lifestyle intervention lowers HbA1c in type 2 diabetes: A feasibility study
by: Nathan R. Weeldreyer, et al.
Published: (2025-01-01)

HbA2:c.96-2A > G mutation: report of 7 cases in China
by: Xiao-Hua Yu, et al.
Published: (2024-12-01)

Relationship between Type 2 Diabetes Mellitus and Red Cell Distribution Width
by: Revan Nasr Salh Abdulla, et al.
Published: (2024-12-01)

Characteristics of insulin prescriptions and their association with glycemic control in adults with type 2 diabetes mellitus
by: Helen Chen, et al.
Published: (2025-07-01)

The role of clinical pharmacists in improving diabetic care of hospitalized heart patients
by: Sanaa Mekdad, et al.
Published: (2025-01-01)

EFFECTIVENESS OF WALKING EXERCISE ON HBA1C AND BMI OF DIABETES MELLITUS TYPE 2: A SYSTEMATIC REVIEW
by: Nurul Fitri, et al.
Published: (2024-12-01)

Genotype–Phenotype Correlation in a Couple in Which the Wife Is a Carrier of the Beta-Thalassemia Trait and the Husband Is a Carrier of a Mutation in the ALAS2 Gene: Both Gene Defects Are Associated with Non-Iron-Deficiency Microcytic Anemia
by: Domenico Dell’Edera, et al.
Published: (2024-12-01)

Poor glycaemic control in type 2 diabetes compromises leukocyte oxygen consumption rate, OXPHOS complex content and neutrophil-endothelial interactions
by: Julia Cacace, et al.
Published: (2025-04-01)

Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
by: Mehmet Birhan Yilmaz, et al.
Published: (2025-04-01)

The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies
by: Gang Fan, et al.
Published: (2025-06-01)

Plant-based Diet for HbA1c Reduction in Type 2 Diabetes Mellitus: an Evidence-based Case Report
by: Denita Biyanda Utami, et al.
Published: (2018-10-01)

Plant-based Diet for HbA1c Reduction in Type 2 Diabetes Mellitus: an Evidence-based Case Report
by: Denita Biyanda Utami, et al.
Published: (2018-10-01)

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01)

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01)

Multistrain Probiotics and Telomere Length in Type 2 Diabetes: A 24-Week Randomized Controlled Trial
by: Venkata Chaithanya, et al.
Published: (2025-02-01)

Correlation Between Serum Uric Acid, Insulin and Hba1c In Type 2 Diabetes Mellitus
by: Maryam Imtiaz, et al.
Published: (2024-06-01)

Impact of Multistrain Probiotic Supplementation on Glycemic Control in Type 2 Diabetes Mellitus—Randomized Controlled Trial
by: Venkata Chaithanya, et al.
Published: (2024-11-01)

Comparative efficacy of Sat-i Gilo and metformin hydrochloride in the management of Type 2 diabetes mellitus: a randomized controlled trial
by: Khan Ameer Kauser Khan, et al.
Published: (2025-08-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
by: Li Liu, et al.
Published: (2025-04-01)

Identification of patients with defects in the globin genes by studying the blood parameters and genetic study: a Case Report
by: Domenico Dell'Edera, et al.
Published: (2014-08-01)

Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control
by: Youssef M. Shalaby, et al.
Published: (2025-12-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now
by: Alessandro Cuttone, et al.
Published: (2025-05-01)

The Correlation Between HbA1c and Neuropathy Disability Score in Type 2 Diabetes
by: Ilsa Hunaifi, et al.
Published: (2021-07-01)

Safety and Efficacy of Imeglimin in Type 2 Diabetes Individuals with Metformin Intolerance: A Case-Control Study
by: Prabhat Agrawal, et al.
Published: (2025-01-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
by: Tapan A. Patel, et al.
Published: (2025-03-01)

Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes
by: Austin Yue Feng Tan, et al.
Published: (2025-08-01)

Sodium-glucose cotransporter 2 Inhibitors and COVID-19 outcomes in type 2 diabetes patients: A population-based cohort study
by: Cerina Dubois, et al.
Published: (2025-07-01)

Is the Presence of a Depressive Disorder a Risk Factor for Worse Metabolic Outcomes Among Patients with Type 2 Diabetes Treated with GLP-1 Analogs?
by: Joana Nicolau, et al.
Published: (2025-07-01)

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial
by: Naimeh Mesri Alamdari, et al.
Published: (2025-07-01)

Diabetes Control and Clinical Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
by: Sameer Kassem, et al.
Published: (2025-07-01)

Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
by: Chinatsu Sakai, et al.
Published: (2025-08-01)